 Effectiveness carboplatin bleomycin combination chemotherapy good-prognosis metastatic testicular nonseminomatous germ cell tumors combination carboplatin bleomycin CEB initial chemotherapy patients good-prognosis metastatic nonseminomatous germ cell tumors NSGCT classification eligible patients Royal Marsden Hospital RMH IM IIA IIB IIC IIIA IIIB courses combination chemotherapy cycle surgical excision residual mass cases laparotomies thoracotomies time analysis median follow-up months start chemotherapy range months cause-specific survival probability single cause-related mortality bleomycin pneumonitis patients CEB chemotherapy combination surgery intensive chemotherapy follow-up completion treatment months toxicity CEB bone marrow suppression alopecia patients significant neurotoxicity ototoxicity minimal renal toxicity patients decrease glomerular filtration rate patients hemoglobin g/dL WBC count nadir treatment cycles platelet nadir Decreases WBC platelet counts brief duration CEB cycles neutropenic sepsis episodes thrombocytopenic purpura bleeding CEB combination effective alternative cisplatin-based chemotherapy good-prognosis NSGCT replacement cisplatin carboplatin leads toxicity